Correction of a chronic pulmonary disease through lentiviral vector-mediated protein expression
Mol Ther Methods Clin Dev. 2022 Apr 14;25:382-391. doi: 10.1016/j.omtm.2022.04.002. eCollection 2022 Jun 9.ABSTRACTWe developed a novel lentiviral vector, pseudotyped with the F and HN proteins from Sendai virus (rSIV.F/HN), that produces long-lasting, high-efficiency transduction of the respiratory epithelium. Here we addressed whether this platform technology can secrete sufficient levels of a therapeutic protein into the lungs to ameliorate a fatal pulmonary disease as an example of its translational capability. Pulmonary alveolar proteinosis (PAP) results from alveolar granulocyte-macrophage colony-stimulating factor (...
Source: Clinical Lung Cancer - May 16, 2022 Category: Cancer & Oncology Authors: Helena Lund-Palau Claudia Ivette Juarez-Molina Cuixiang Meng Anushka Bhargava Aikaterini Pilou Kiran Aziz Nora Clarke Naoko Atsumi Ali Ashek Michael R Wilson Masao Takata Simon Padley Deborah R Gill Stephen C Hyde Cliff Morgan Eric W F W Alton Uta Griesen Source Type: research

Presence of a Ground-Glass Opacity Component Is the True Prognostic Determinant in Clinical Stage I NSCLC
CONCLUSIONS: These results suggest that presence of GGO is the true prognostic determinant of stage I NSCLC, irrespective of the size of the solid component. Our novel T descriptor classification system could more accurately predict prognoses of clinical stage I NSCLC cases.PMID:35574192 | PMC:PMC9097453 | DOI:10.1016/j.jtocrr.2022.100321 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - May 16, 2022 Category: Cancer & Oncology Authors: Akira Hamada Kenichi Suda Toshio Fujino Masaya Nishino Shuta Ohara Takamasa Koga Takanobu Kabasawa Masato Chiba Masaki Shimoji Makoto Endoh Toshiki Takemoto Junichi Soh Naoki Yanagawa Satoshi Shiono Tetsuya Mitsudomi Source Type: research

Timing is everything: The importance of patient-reported outcome assessment frequency when characterizing symptomatic adverse events
CONCLUSION: This analysis demonstrates that more frequent assessment of patient-reported symptomatic adverse events will lead to improved detection, and therefore a more complete understanding of the tolerability of experimental anti-cancer therapies.PMID:35575012 | DOI:10.1177/17407745221093935 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - May 16, 2022 Category: Cancer & Oncology Authors: Bellinda L King-Kallimanis Vishal Bhatnagar Erica G Horodniceanu Ting-Yu Chen Paul G Kluetz Source Type: research

Factors Related to the Caregiving Burden on Families of Korean Patients With Lung Cancer
Clin Nurs Res. 2022 May 16:10547738221098150. doi: 10.1177/10547738221098150. Online ahead of print.ABSTRACTThe purposes of this study were to describe caregiver burden on families of patients with lung cancer and to examine its associated factors, including patient symptoms and symptom clusters. In this cross-sectional study, 120 patient-caregiver dyads were recruited from an outpatient clinic in a tertiary care hospital. Patient symptoms and caregiver burden were measured with structured questionnaire. Descriptive and inferential statistics were used to analyze data. Three patient symptom clusters were identified. Hierar...
Source: Clinical Lung Cancer - May 16, 2022 Category: Cancer & Oncology Authors: Hyun Jung Lee Soo Kyung Park Source Type: research

Glaucocalyxin A induces apoptosis of NSCLC cells by inhibiting the PI3K/Akt/GSK3 β pathway
This study characterizes the anti-cancer effects of Glaucocalyxin A (GLA) and explores the underlying mechanisms using human non-small cell lung carcinoma (NSCLC) cells. First, our data showed that GLA suppressed the viability of cancer cells, while no effect was observed in the normal bronchial epithelial cell Bease 2B cells. Second, GLA inhibited colony formation, induced apoptosis of cancer cells. Third, GLA down-regulated the expression of B-cell lymphoma-2 (Bcl-2) protein, up-regulated the expression of Bcl2-associated X protein (Bax) , and strengthened cleavage of Caspase-3 and poly ADP-ribose polymerase (PARP). Four...
Source: Clinical Lung Cancer - May 16, 2022 Category: Cancer & Oncology Authors: De Zhang Ting Deng Wa Yuan Tongqiang Chen Shuping Jiang Source Type: research

Serum transfer RNA-derived fragment tRF-31-79MP9P9NH57SD acts as a novel diagnostic biomarker for non-small cell lung cancer
CONCLUSION: serum tRF-31-79MP9P9NH57SD possibly is a new and groundbreaking biomarker for the NSCLC.PMID:35576497 | DOI:10.1002/jcla.24492 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - May 16, 2022 Category: Cancer & Oncology Authors: Jipeng Li Chao Cao Laifu Fang Wanjun Yu Source Type: research

Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline
J Clin Oncol. 2022 May 16:JCO2200687. doi: 10.1200/JCO.22.00687. Online ahead of print.ABSTRACTPURPOSE: To provide guidance on exercise, diet, and weight management during active cancer treatment in adults.METHODS: A systematic review of the literature identified systematic reviews and randomized controlled trials evaluating the impact of aerobic and resistance exercise, specific diets and foods, and intentional weight loss and avoidance of weight gain in adults during cancer treatment, on quality of life, treatment toxicity, and cancer control. PubMed and the Cochrane Library were searched from January 2000 to May 2021. A...
Source: Clinical Lung Cancer - May 16, 2022 Category: Cancer & Oncology Authors: Jennifer A Ligibel Kari Bohlke Anne M May Steven K Clinton Wendy Demark-Wahnefried Susan C Gilchrist Melinda L Irwin Michele Late Sami Mansfield Timothy F Marshall Jeffrey A Meyerhardt Cynthia A Thomson William A Wood Catherine M Alfano Source Type: research

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)
CONCLUSION: The efficacy of neoadjuvant chemotherapy plus nivolumab in resectable NSCLC is supported by 3-year OS. ctDNA levels were significantly associated with OS and outperformed radiologic assessments in the prediction of survival.PMID:35576508 | DOI:10.1200/JCO.21.02660 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - May 16, 2022 Category: Cancer & Oncology Authors: Mariano Provencio Roberto Serna-Blasco Ernest Nadal Amelia Insa M Rosario Garc ía-Campelo Joaqu ín Casal Rubio Manuel D ómine Margarita Majem Delvys Rodr íguez-Abreu Alex Mart ínez-Martí Javier De Castro Carpe ño Manuel Cobo Guillermo L ópez Vivan Source Type: research

Allele frequency and proportion defined by circulating tumor DNA profiling predict tyrosine kinase inhibitors' therapeutic outcomes for non-small cell lung cancer
CONCLUSION: The frequency and proportion of ctDNA mutations are worth clinical attention in the prediction of therapeutic outcomes.PMID:35578031 | DOI:10.1007/s00432-022-03992-5 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - May 16, 2022 Category: Cancer & Oncology Authors: Jiajia Song Ling Bai Jianzhao Zhai Zhaodan Xin Liting You Yi Zhou Juan Zhou Binwu Ying Source Type: research

Heal-me PiONEer (personalized online nutrition and exercise): An RCT assessing 2 levels of app-based programming in individuals with chronic disease
Conclusions The Heal-Me PiONEer RCT holds promise to provide a comprehensive understanding of the delivery and impact of app-based nutrition and exercise programming in a diverse group of participants with chronic disease.PMID:35569753 | DOI:10.1016/j.cct.2022.106791 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - May 15, 2022 Category: Cancer & Oncology Authors: Puneeta Tandon Graeme Purdy Kathleen P Ismond Christofer Cruz Evelyn Etruw Kirsten Suderman Ashley Hyde Michael Stickland John C Spence Dale C Lien Rahima Bhanji Carla M Prado Antonio Miguel Cruz Anil A Joy Maryna Yaskina Jeff Round Kate Harback Raj Padwa Source Type: research

Impact of COPD Treatment on Survival in Patients with Advanced Non-Small Cell Lung Cancer
J Clin Med. 2022 Apr 24;11(9):2391. doi: 10.3390/jcm11092391.ABSTRACTChronic obstructive pulmonary disease (COPD) is associated with a poor prognosis in patients with non-small cell lung cancer (NSCLC). However, the impact of COPD treatment on the survival of patients with advanced NSCLC remains uncertain. We retrospectively investigated COPD patients among patients newly diagnosed with advanced NSCLC between September 2005 and August 2019 at a university hospital. The clinical characteristics, lung function, and survival outcomes were analyzed and compared between patients who did and did not receive COPD treatment. Among...
Source: Clinical Lung Cancer - May 14, 2022 Category: Cancer & Oncology Authors: Hyunji Jo Sojung Park Nam Eun Kim So Young Park Yon Ju Ryu Jung Hyun Chang Jin Hwa Lee Source Type: research

< em > FGFR < /em > Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC)
CONCLUSIONS: Over 23% of FGFR2/3 fusions in aNSCLC may be associated with acquired resistance following treatment with EGFR TKIs. In this clinical scenario, a combination of EGFR TKIs and FGFR TKIs represents a promising treatment strategy.PMID:35566609 | PMC:PMC9102087 | DOI:10.3390/jcm11092475 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - May 14, 2022 Category: Cancer & Oncology Authors: Ari Raphael Elizabeth Dudnik Dov Hershkovitz Suyog Jain Steve Olsen Lior Soussan-Gutman Taly Ben-Shitrit Addie Dvir Hovav Nechushtan Nir Peled Amir Onn Abed Agbarya None On Behalf Of The Israel Lung Cancer Group Source Type: research

Bereaved Family Members' Perspectives of Good Death and Quality of End-of-Life Care for Malignant Pleural Mesothelioma Patients: A Cross-Sectional Study
CONCLUSIONS: The quality of end-of-life care for MPM patients remains poor. Moreover, MPM patients do not achieve good deaths from the perspective of their bereaved family members.PMID:35566667 | PMC:PMC9099626 | DOI:10.3390/jcm11092541 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - May 14, 2022 Category: Cancer & Oncology Authors: Yasuko Nagamatsu Yumi Sakyo Edward Barroga Riwa Koni Yuji Natori Mitsunori Miyashita Source Type: research

Neoadjuvant Chemo-Immunotherapy for Locally Advanced Non-Small-Cell Lung Cancer: A Review of the Literature
In conclusion, neoadjuvant immunotherapy whether combined or not with chemotherapy reveals a promising survival benefit for patients with advanced non-small-cell lung cancer; nevertheless, more data remain necessary to identify the best candidates for neoadjuvant regimens.PMID:35566754 | PMC:PMC9099888 | DOI:10.3390/jcm11092629 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - May 14, 2022 Category: Cancer & Oncology Authors: Sara Franzi Giovanni Mattioni Erika Rijavec Giorgio Alberto Croci Davide Tosi Source Type: research

Trends of cancer mortality in Xi'an City, China: 2005-2020
CONCLUSIONS: Malignant tumors in Xi'an have decreasing mortality trends in recent years, and effective measures to prevent and treat tumors should be strengthened in the future.PMID:35567625 | DOI:10.1007/s00432-022-04046-6 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - May 14, 2022 Category: Cancer & Oncology Authors: Ning Chen Xiao-Yu Zhang Lin-Lin Ma Guo-Dong Zhao Yu-Xiang Yan Source Type: research